The Cutting Edge of Oncologoical, Neurological, and Cardiac and Metabolic Treatments
Innovation capability is the core competence of Luye Pharma. The company has built up an R&D system of international standards, which has brought the company up to the world’s most advanced level in the research of new drug delivery technologies and biologics.
Drug Delivery Approaches
Many therapeutics such as peptide and protein, antibody, and small molecule drugs, in general may not be administered using traditional delivery routes because they might be susceptible to enzymatic degradation or can not be absorb the systemic circulation efficiently. We are developing novel formulations, and devices to overcome these limitations.
Novel DDS Pipeline
A solid pre-clinical pipeline is being developed based on our cutting-edge delivery systems. The pipeline include novel and generic small molecules, proteins, and even cell therapies, delivered in radically new ways to enable much more efficient delivery, especially in tumors, at much lower concentrations.
Biologics are therapeutics made from living cells through highly complex manufacturing processes and must be handled and administered under carefully monitored conditions. Biologics are used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases.
Luye Boston is approaching biologics in a very innovative and robust way. Our pipeline covers monoclonal antibodies, bi-specific antibodies, low-molecular-weight peptides, as well as cellular therapeutics. We cover a variety of indications including oncology, neuro degenerative diseases, and metabolic disorders.
The main pillar of our biologic strategy is to deliver innovation globally. The portfolio decision-making process has been improved and a rigorous project prioritization implemented with shorter timelines to phase transitions. Efficiency in R&D has been strengthened with the development of novel platforms to develop next generation biologics, with the goal to improve patient outcomes, and with a focus on selected core therapeutic areas. Our biologics group has two priority development programs: immuno-oncology via proteins and peptides, and cellular therapeutics.
The Luye Boston R&D formulation group offers unparalleled formulation and drug delivery system support, from ideation through IND submission and tech transfer. Our solutions focus on bioavailability enhancement and customized development. With our high level of expertise for various pharmaceutical applications, we provide extensive expertise for our novel projects and throughout the entire life cycle of our clinical-stage products.